Tandem autologous hematopoietic stem cell transplantation for patients with multiple myeloma: a systematic review and meta-analysis

Reference

• Rajkumar SV, Kumar S. Multiple myeloma current treatment algorithms. Blood Cancer J. 2020;10(9):94. doi:10.1038/s41408-020-00359-2
   PubMed Web of Science ®Google Scholar
• Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022;97(8):1086–1107. doi:10.1002/ajh.26590
   PubMed Web of Science ®Google Scholar
• Al Hamed R, Bazarbachi AH, Malard F, et al. Current status of autologous stem cell transplantation for multiple myeloma. Blood Cancer J. 2019;9(4):44. doi:10.1038/s41408-019-0205-9
   PubMedGoogle Scholar
• Morè S, Corvatta L, Manieri VM, et al. Autologous stem cell transplantation in multiple myeloma: where are we and where do we want to go? Cells. 2022;11(4):606. doi:10.3390/cells11040606
   PubMed Web of Science ®Google Scholar
• San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359(9):906–917. doi:10.1056/NEJMoa0801479
   PubMed Web of Science ®Google Scholar
• Barlogie B, Jagannath S, Vesole DH, et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood. 1997;89(3):789–793. doi:10.1182/blood.V89.3.789
   PubMed Web of Science ®Google Scholar
• Attal M, Harousseau JL, Facon T, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med. 2003;349(26):2495–2502. doi:10.1056/NEJMoa032290
   PubMed Web of Science ®Google Scholar
• Cavo M, Tosi P, Zamagni E, et al. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol. 2007;25(17):2434–2441. doi:10.1200/JCO.2006.10.2509
   PubMed Web of Science ®Google Scholar
• Kaloyannidis P, Apostolidis J. Allogeneic stem cell transplantation in patients with high-risk multiple myeloma: utopia or continuous challenge in aiming for cure? Curr Treat Options Oncol. 2021;22(8):65. doi:10.1007/s11864-021-00864-x
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. doi:10.1371/journal.pmed.1000097
   PubMed Web of Science ®Google Scholar
• Lee YH. An overview of meta-analysis for clinicians. Korean J Intern Med. 2018;33(2):277–283. doi:10.3904/kjim.2016.195
   PubMed Web of Science ®Google Scholar
• Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17(24):2815–2834. doi:10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8
   PubMed Web of Science ®Google Scholar
• Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16. doi:10.1186/1745-6215-8-16
   PubMed Web of Science ®Google Scholar
• Dingli D, Pacheco JM, Dispenzieri A, et al. In vivo and in silico studies on single versus multiple transplants for multiple myeloma. Cancer Sci. 2007;98(5):734–739. doi:10.1111/j.1349-7006.2007.00450.x
   PubMed Web of Science ®Google Scholar
• Mai EK, Benner A, Bertsch U, et al. Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long-term results from the phase III GMMG-HD2 trial. Br J Haematol. 2016;173(5):731–741. doi:10.1111/bjh.13994
   PubMed Web of Science ®Google Scholar
• Stadtmauer EA, Pasquini MC, Blackwell B, et al. Autologous transplantation, consolidation, and maintenance therapy in multiple myeloma: results of the BMT CTN 0702 trial. J Clin Oncol. 2019;37(7):589–597. doi:10.1200/JCO.18.00685
   PubMed Web of Science ®Google Scholar
• Straka C, Salwender H, Knop S, et al. Full or intensity-reduced high-dose melphalan and single or double autologous stem cell transplant with or without bortezomib consolidation in patients with newly diagnosed multiple myeloma. Eur J Haematol. 2021;107(5):529–542. doi:10.1111/ejh.13690
   PubMed Web of Science ®Google Scholar
• Garban F, Attal M, Michallet M, et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood. 2006;107(9):3474–3480. doi:10.1182/blood-2005-09-3869
   PubMed Web of Science ®Google Scholar
• Htut M, D'Souza A, Krishnan A, et al. Autologous/allogeneic hematopoietic cell transplantation versus tandem autologous transplantation for multiple myeloma: comparison of long-term postrelapse survival. Biol Blood Marrow Transplant. 2018;24(3):478–485. doi:10.1016/j.bbmt.2017.10.024
   PubMedGoogle Scholar
• Krishnan A, Pasquini MC, Ewell M, et al. Tandem autologous hematopoietic stem cell transplants (AuHCT) with or without maintenance therapy (auto-auto) versus single AuHCT followed by HLA matched sibling non-myeloablative allogeneic HCT (auto-allo) for patients with standard risk (SR) multiple myeloma (MM): results from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0102 Trial. Blood. 2010;116(21):41. doi:10.1182/blood.V116.21.41.41
   Web of Science ®Google Scholar
• Rosiñol L, Pérez-Simón JA, Sureda A, et al. A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood. 2008;112(9):3591–3593. doi:10.1182/blood-2008-02-141598
   PubMed Web of Science ®Google Scholar
• Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111(5):2516–2520. doi:10.1182/blood-2007-10-116129
   PubMed Web of Science ®Google Scholar
• Palumbo A, Facon T, Sonneveld P, et al. Thalidomide for treatment of multiple myeloma: 10 years later. Blood. 2008;111(8):3968–3977. doi:10.1182/blood-2007-10-117457
   PubMed Web of Science ®Google Scholar
• Ricciuti G, Falcone A, Cascavilla N, et al. Autologous stem cell transplantation in multiple myeloma. Panminerva Med. 2020;62(4):220–224.
   PubMed Web of Science ®Google Scholar
• Costa LJ, Zhang MJ, Zhong X, et al. Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma. Biol Blood Marrow Transplant. 2013;19(11):1615–1624. doi:10.1016/j.bbmt.2013.08.002
   PubMed Web of Science ®Google Scholar
• Passweg JR, Baldomero H, Bader P, et al. Hematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants. Bone Marrow Transplant. 2015;50(4):476–482. doi:10.1038/bmt.2014.312
   PubMed Web of Science ®Google Scholar
• Fermand JP, Ravaud P, Chevret S, et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood. 1998;92(9):3131–3136. doi:10.1182/blood.V92.9.3131
   PubMed Web of Science ®Google Scholar
• Perrot A, Lauwers-Cances V, Cazaubiel T, et al. Early versus late autologous stem cell transplant in newly diagnosed multiple myeloma: long-term follow-up analysis of the IFM 2009 trial. Blood. 2020;136(Supplement 1):39. doi:10.1182/blood-2020-134538
   Web of Science ®Google Scholar
• Kumar A, Kharfan-Dabaja MA, Glasmacher A, et al. Tandem versus single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis. J Natl Cancer Inst. 2009;101(2):100–106. doi:10.1093/jnci/djn439
   PubMedGoogle Scholar
• Dhakal B, Szabo A, Chhabra S, et al. Autologous transplantation for newly diagnosed multiple myeloma in the era of novel agent induction: a systematic review and meta-analysis. JAMA Oncol. 2018;4(3):343–350. doi:10.1001/jamaoncol.2017.4600
   PubMed Web of Science ®Google Scholar
• Armeson KE, Hill EG, Costa LJ. Tandem autologous vs autologous plus reduced intensity allogeneic transplantation in the upfront management of multiple myeloma: meta-analysis of trials with biological assignment. Bone Marrow Transplant. 2013;48(4):562–567. doi:10.1038/bmt.2012.173
   PubMed Web of Science ®Google Scholar
• Kharfan-Dabaja MA, Hamadani M, Reljic T, et al. Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. J Hematol Oncol. 2013;6:2. doi:10.1186/1756-8722-6-2
   PubMed Web of Science ®Google Scholar